Tippapatt
Shares of Qualigen Therapeutics (NASDAQ:QLGN) fell 21% on Tuesday following news that the company plans to participate in a funding round for Israeli medtech NanoSynex.
The Carlsbad, Calif.-based oncology drug developer said it will be the first investor participating in a bridge round for NanoSynex, which plans to raise up to $500K, according to a statement.
In December, Qualigen (NASDAQ:QLGN) announced it had regained compliance with Nasdaq’s minimum bid price and stockholders’ equity requirements.
